Gates Foundation Partners with Indian Drugmakers to Speed Rollout of $40 HIV Shot

Gates Foundation partners with Indian drugmakers to speed rollout of $40 HIV shot

A twice-yearly injection described as the most promising HIV prevention tool in decades is poised to reach millions more people, with new generic versions priced at about $40 per patient per year.

Indian drugmakers Dr Reddy’s, Hetero to sell generic HIV prevention drug for $40 a year

Experts say twice-a-year injection could help end Aids crisis

Gates Foundation, Indian firm to produce $40 twice-yearly HIV prevention shot

The announcement comes at a troubling time for global health, particularly in the fight against HIV/AIDS, as US foreign aid faces sharp cuts under the Trump administration.

Gates Foundation Partners With Indian Drugmakers to Speed Rollout of $40 HIV Shot

Gates Foundation Partners with Indian Manufacturer to Make HIV Prevention Injection Affordable

​NEW YORK Sep 26 – Millions more people at risk of HIV in low- and middle-income countries (LMICs) will have access to a powerful new prevention option: a low-cost, generic version of lenacapavir, the world’s first twice-yearly injectable pre-exposure prophylaxis (PrEP).  A new partnership announced today between the Gates Foundation and Indian manufacturer Hetero Labs (Hetero)—supported by upfront funding and volume guarantees—will enable the c…

Transforming the fight against HIV

Many millions more people at risk of HIV in low- and middle-income countries will have access to a powerful new prevention option thanks to the Gates Foundation and Indian drug manufacturer Hetero Labs. The two organisations have partnered to produce a low-cost, generic version of lenacapavir, the world’s first twice-yearly injectable pre-exposure prophylaxis (PrEP), at roughly $40 per patient per year (after a short pre-treatment oral regimen) …